Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New throat sprays aim to soothe your cold cough

NCT ID NCT07330856

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two throat sprays (CDN and CW) for adults with a cough from a viral cold. About 58 people will use one of the sprays for 7 days and report how well it works and any side effects. The goal is to see if these sprays are safe and help ease cough symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 58 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, * Aged 18 to 65 years, * Presenting with an acute dry or productive cough for less than 3 weeks, associated with one of the following viral conditions: Acute viral rhinitis, Acute viral rhinopharyngitis, Acute viral tonsillitis, Acute viral pharyngitis / tonsillitis, * For patients with suspected pharyngitis/tonsillitis: McIsaac score \< 2 or a negative rapid antigen detection test for Group A beta-hemolytic Streptococcus, * Effective contraception for female patients of childbearing potential, * Sufficient cooperation and understanding to comply with the requirements of the trial, * Acceptance of registration in the SI-RIPH database (Système d'Information pour la Recherche sur les Produits de Santé), * Having received clear information and agreeing to provide written informed consent, * Covered by the French national health insurance system Exclusion Criteria: * Hypersensitivity or history of allergy to any component of the investigational products, * Severe, poorly tolerated cough, * Complicated acute rhinitis (e.g., acute bacterial sinusitis, acute otitis media, acute bronchitis, or pneumonia), * Chronic or allergic rhinosinusitis, * Bacterial tonsillitis or pharyngitis, * Positive antigen test for influenza A/B or COVID-19 requiring etiological treatment per current guidelines (Appendix 5), * Concurrent use of antitussives, bronchodilators, inhaled corticosteroids, other pulmonary-targeted therapies, or medications known to induce cough (such as ACE inhibitors, ARBs, etc.), antibiotics, antivirals, or any other treatment deemed incompatible with the study by the investigator, * Recent ENT surgery (\<6 months), * Pulmonary disease (e.g., COPD, asthma), * Immunodeficiency (based on patient declaration), * Comorbidities or a health status judged incompatible with the trial by the investigator (e.g., Gastroesophageal Reflux Disease \[GERD\] or abnormal lung auscultation), * Pregnant or breastfeeding women, * Regular tobacco smoker (as judged by the investigator), * Current participation in another clinical trial, being in an exclusion period from a previous trial, or having received total compensation exceeding 6000 euros in the 12 months prior to study start, * Under legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial safeguard).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute viral pharyngitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Clermont-ferrand

    RECRUITING

    Clermont-Ferrand, 63000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.